Arrowpoint Investment Partners Singapore Pte. Ltd. Takes $576,000 Position in Hologic, Inc. $HOLX

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,539 shares of the medical equipment provider’s stock, valued at approximately $576,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Perbak Capital Partners LLP lifted its stake in Hologic by 104.0% during the third quarter. Perbak Capital Partners LLP now owns 20,694 shares of the medical equipment provider’s stock worth $1,397,000 after purchasing an additional 10,548 shares in the last quarter. Brown Brothers Harriman & Co. lifted its position in shares of Hologic by 10.1% during the third quarter. Brown Brothers Harriman & Co. now owns 4,678 shares of the medical equipment provider’s stock worth $316,000 after purchasing an additional 428 shares in the last quarter. Pathstone Holdings LLC boosted its stake in shares of Hologic by 0.4% in the third quarter. Pathstone Holdings LLC now owns 53,809 shares of the medical equipment provider’s stock valued at $3,632,000 after purchasing an additional 207 shares during the period. Eisler Capital Management Ltd. acquired a new position in shares of Hologic in the third quarter valued at approximately $218,000. Finally, Vise Technologies Inc. acquired a new position in shares of Hologic in the third quarter valued at approximately $236,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on HOLX shares. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Evercore cut Hologic from an “outperform” rating to an “in-line” rating and decreased their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Trading Down 0.1%

NASDAQ HOLX opened at $75.12 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The firm’s fifty day moving average price is $75.13 and its 200 day moving average price is $72.64. The company has a market capitalization of $16.77 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.75.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $0.87 earnings per share. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.